Tempus AI Inc
For the period ended Sep 30, 2024. Filed Nov 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 4, 2024
TEM$80.54-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net revenue | ||||
| Genomics | $116,422 | $96,815 | $331,315 | $270,797 |
| Data and services | 64,507 | 39,242 | 161,403 | 113,301 |
| Total net revenue | $180,929 | $136,057 | $492,718 | $384,098 |
| Cost and operating expenses | ||||
| Cost of revenues, genomics | 60,126 | 46,540 | 181,285 | 138,781 |
| Cost of revenues, data and services | 14,964 | 15,490 | 52,384 | 40,690 |
| Technology research and development | 30,680 | 24,156 | 135,655 | 70,485 |
| Research and development | 27,348 | 23,234 | 119,713 | 66,268 |
| Selling, general and administrative | 101,427 | 71,426 | 644,063 | 211,662 |
| Total cost and operating expenses | 234,545 | 180,846 | 1,133,100 | 527,886 |
| Loss from operations | $(53,616) | $(44,789) | $(640,382) | $(143,788) |
| Interest income | 4,789 | 1,483 | 7,538 | 5,864 |
| Interest expense | (13,761) | (12,342) | (40,294) | (33,245) |
| Other (expense) income, net | (11,522) | 2,287 | (17,821) | 7,909 |
| Loss before provision for income taxes | $(74,110) | $(53,361) | $(690,959) | $(163,260) |
| Provision for income taxes | (38) | (65) | (144) | (74) |
| Losses from equity method investments | (1,692) | — | (1,692) | (301) |
| Net Loss | $(75,840) | $(53,426) | $(692,795) | $(163,635) |
| Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares | — | (11,143) | (39,347) | (32,709) |
| Cumulative undeclared dividends on Series C preferred shares | — | (764) | (1,174) | (2,230) |
| Net loss attributable to common shareholders, basic and diluted | (75,840) | (65,333) | (733,316) | (198,574) |
| Net loss per share attributable to common shareholders, basic and diluted | $(0.46) | $(1.03) | $(7.04) | $(3.14) |
| Weighted-average shares outstanding used to compute net loss per share, basic and diluted | 165,612 | 63,286 | 104,164 | 63,267 |
| Comprehensive Loss, net of tax | ||||
| Net loss | $(75,840) | $(53,426) | $(692,795) | $(163,635) |
| Foreign currency translation adjustment | 10,302 | (54) | 10,203 | (29) |
| Comprehensive loss | $(65,538) | $(53,480) | $(682,592) | $(163,664) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.